OCRX Ocera Therapeutics, Inc.

1.13
-0.01  -1%
Previous Close 1.14
Open 1.14
Price To book 1.71
Market Cap 26.67M
Shares 23,600,000
Volume 258,505
Short Ratio 1.11
Av. Daily Volume 2,331,460

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released January 30, 2017 - primary endpoint not met. Plans to meet with FDA 3Q 2017 - noted March 8, 2017.
OCR-002 (IV)
Hepatic encephalopathy
Phase 2a trial to be initiated 1H 2017.
OCR-002
Cirrhosis

Latest News

  1. Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, June 2
  2. Edited Transcript of OCRX earnings conference call or presentation 9-May-17 8:30pm GMT
  3. Ocera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical Update
  4. Investor Network: Ocera Therapeutics, Inc. to Host Earnings Call
  5. ETFs with exposure to Ocera Therapeutics, Inc. : May 3, 2017
  6. Ocera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 2017
  7. Today's Research Reports on Biotech Stocks to Watch: Ocera Therapeutics and Verastem
  8. Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)
  9. ETFs with exposure to Ocera Therapeutics, Inc. : April 7, 2017
  10. Ocera to Present at the 16th Annual Needham Healthcare Conference
  11. ETFs with exposure to Ocera Therapeutics, Inc. : March 27, 2017
  12. Ocera Therapeutics, Inc. :OCRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  13. Ocera Therapeutics, Inc. :OCRX-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
  14. Here’s What’s Moving Immunomedics, Inc. (IMMU) And Ocera Therapeutics Inc (OCRX)
  15. Ocera Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
  16. Biotech and Pharmaceutical Stocks Fall on Pricing Concerns: Today's Research Reports on Ocera Therapeutics and Array Biopharma
  17. Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy
  18. Five Penny Stocks to Buy Now
  19. Ocera to Present at the Cowen and Company 37th Annual Healthcare Conference
  20. Lifshitz & Miller LLP Announces Investigation of Centrue Financial Corporation, Motorola Solutions, Inc., Natus Medical Incorporated, Northern Dynasty Minerals Ltd., Ocera Therapeutics, Inc., Psychemedics Corporation, RH and Stemline Therapeutics, Inc.